MeiraGTx Holdings plc - Ordinary Shares (NQ:MGTX)

7.970 -0.300 (-3.63%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist

Price and Volume

Volume	267,441
Open	8.250
Bid (Size)	7.940 (3,300)
Ask (Size)	7.960 (1,400)
Prev. Close	8.270
Today's Range	7.890 - 8.250
52wk Range	4.550 - 9.730
Shares Outstanding	80,479,684
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The Biotech Tug-of-War: Is Kiora Pharmaceuticals Positioned to Ride the 2025 Commodity Wave?

December 18, 2025

As of December 18, 2025, the financial landscape is defined by a stark divergence in the commodities market, creating a complex environment for clinical-stage biotechnology firms. While gold prices...

Via MarketMinute

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

November 13, 2025

From MeiraGTx

Via GlobeNewswire

Performance

YTD	+27.1%	+27.1%
1 Month	+5.1%	+5.1%
3 Month	-2.7%	-2.7%
6 Month	+19.5%	+19.5%
1 Year	+30.4%	+30.4%

More News

MGTX Stock Soared 13% Today – What’s The Eli Lilly Angle? ↗

November 10, 2025

Via Stocktwits

Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration ↗

November 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

November 10, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

October 07, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Sales Jump 1,133 Percent ↗

August 14, 2025

Via The Motley Fool

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

August 14, 2025

From MeiraGTx

Via GlobeNewswire

Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

May 14, 2025

Via Benzinga

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 13, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

May 09, 2025

From MeiraGTx

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 13, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

March 13, 2025

Via Chartmill

Crude Oil Falls 1%; Dollar General Posts Upbeat Sales ↗

March 13, 2025

Via Benzinga

G-III Apparel Posts Better-Than-Expected Earnings, Joins Ballard Power Systems, Dollar General And Other Big Stocks Moving Higher On Thursday ↗

March 13, 2025

Via Benzinga

MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars ↗

March 13, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 13, 2025

Via Benzinga

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

March 13, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

March 13, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

February 21, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

January 22, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

December 09, 2024

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates

November 13, 2024

From MeiraGTx

Via GlobeNewswire

Frequently Asked Questions

Is MeiraGTx Holdings plc - Ordinary Shares publicly traded?

Yes, MeiraGTx Holdings plc - Ordinary Shares is publicly traded.

What exchange does MeiraGTx Holdings plc - Ordinary Shares trade on?

MeiraGTx Holdings plc - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for MeiraGTx Holdings plc - Ordinary Shares?

The ticker symbol for MeiraGTx Holdings plc - Ordinary Shares is MGTX on the Nasdaq Stock Market

What is the current price of MeiraGTx Holdings plc - Ordinary Shares?

The current price of MeiraGTx Holdings plc - Ordinary Shares is 7.970

When was MeiraGTx Holdings plc - Ordinary Shares last traded?

The last trade of MeiraGTx Holdings plc - Ordinary Shares was at 12/26/25 04:00 PM ET

What is the market capitalization of MeiraGTx Holdings plc - Ordinary Shares?

The market capitalization of MeiraGTx Holdings plc - Ordinary Shares is 641.42M

How many shares of MeiraGTx Holdings plc - Ordinary Shares are outstanding?

MeiraGTx Holdings plc - Ordinary Shares has 641M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.